Beller NS, Beller M, Murmann JJ, Crisp R (2025)
Publication Type: Journal article
Publication year: 2025
Book Volume: 61
Article Number: 127392
DOI: 10.1016/j.vaccine.2025.127392
Adverse events (AE) of varying severity commonly occur after vaccinations, potentially related to the nocebo effect. The randomized single-center clinical trial “LIFe Study” at the Vaccination Center Lichtenfels, Germany, investigates AE based on doctor-patient interaction and administered vaccine type following COVID-19 vaccination. Vaccinees receiving first or second doses were randomized: the control group (n=1,006) received in-depth medical briefings elaborating all possible AE; the experimental group (n=937) concise medical briefings comprising only medically relevant facts to the. Nocebo effects were quantified by self-reported AE frequency and severity; then AE across vaccine types and vaccinee demographics were compared including vaccinees receiving third (booster) doses. Questionnaires allowed rating 12 listed AE from absent, mild, moderate, to severe (valued as {0,1,2,3}, respectively), and summed to yield a score ranging from 0 to 36. Most AE were mild with no significant difference in mean AE (mAE) score between control (3.95, σ = 4.70) and experimental groups (3.96, σ = 4.75), nor in the number of participants reporting drug use for symptom relief (n
APA:
Beller, N.S., Beller, M., Murmann, J.J., & Crisp, R. (2025). Impact of the medical briefing and vaccine type on adverse events following COVID-19 vaccination: A randomized clinical trial. Vaccine, 61. https://doi.org/10.1016/j.vaccine.2025.127392
MLA:
Beller, Nora S., et al. "Impact of the medical briefing and vaccine type on adverse events following COVID-19 vaccination: A randomized clinical trial." Vaccine 61 (2025).
BibTeX: Download